Every year, the ground moved. Every time, practices paid for it.
None of these disruptions were caused by prescribers. All of them landed on prescribers.
Compounded GLP-1 access opened, then closed
Semaglutide and tirzepatide came off the FDA shortage list, and the legal basis for compounding shifted underneath every pharmacy selling them. Products that anchored a practice's protocol disappeared on a deadline.
State-by-state restrictions, one map, fifty rulebooks
Boards of pharmacy tightened rules unevenly. A pharmacy fully compliant in one state lost the ability to ship into another, and every affected patient needed a new dispensing path immediately.
The product you titrated on stopped existing
Strengths were discontinued, combinations reformulated, vial sizes changed. Titration schedules built on one catalog broke against the next one.
And when a pharmacy left the space, its prescribers started over
New accounts, new portals, new reps, new prices, new paperwork. For many practices, this cycle has now run three or four times. The pharmacy changed; the work of changing was yours.
The migration cycle ends here
The Hub absorbs the next disruption instead of forwarding it to you. Multiple contracted pharmacies stand behind one agreement, one catalog, one price sheet, and one point of contact, so regulatory shocks change our routing, not your operations.